Garrett Missed This Trade... | BioNTech Share Is Favorably Valued

[] Sometimes the best thing to do is nothing, especially on a Friday. There’s an important lesson that investors must learn about not chasing trades, ever. [View in browser]( . Sometimes the best thing to do is nothing, especially on a Friday. There’s an important lesson that investors must learn about not chasing trades, ever. [View in browser]( . . [] [Havens Investment Letter] [] [Havens Investment Letter] [] [] [] 2-Decade Trading Veteran: I want as many people as possible to know about this Legendary trader Rob Booker is on to something. Why are newsletters so popular... when you have to wait a month to receive stock picks? He’s found the solution that the big-wigs will never tell you. [See this and never wait for a monthly stock pick again.]( [] --------------------------------------------------------------- [] 2-Decade Trading Veteran: I want as many people as possible to know about this Legendary trader Rob Booker is on to something. Why are newsletters so popular... when you have to wait a month to receive stock picks? He’s found the solution that the big-wigs will never tell you. [See this and never wait for a monthly stock pick again.]( [] --------------------------------------------------------------- [] [] I Missed This Trade... [Garrett Pic] Dear Investor, Today, I woke up more bullish than I was on March 17. A short-term pop felt like it was inevitable. I was ready to load up on a day-trade and bet big on the QQQ. And I was especially bullish on a consumer discretionary stock that had a big insider buy. My plan was in place at 9:23 am. But then I received a phone call. My project over in Europe is surprisingly doing well thanks to the shift in the winds on alternative energy. I was surprised… and happy. So, I talked to my project leader… for an hour. As a result, I missed a trade that would have paid off big. I was mad for five minutes. But I quickly got over it. I’ll explain why. And one of the most important lessons of this market. Don’t Chase… Ever I was bullish today for several reasons. First, the VIX hasn’t elevated as high as most investors thought it would. Most people think that the VIX must move higher when stocks are moving lower. But that’s not how it works. The reality is that most traders are already hedged, and without more hedging entering the fold, the VIX doesn’t start to go bonkers. Next, the VIX is historically low when you consider the severity of the downside move. There is short-term bias in this market, and people think that the VIX will just run to 40, 60, or 80. That’s not how it works. I was also bullish today because I’ve seen this hyper-bearish pattern three times in 2022 and in late March 2022. Sometimes things get so bearish that you have to become bullish. One of the finest rules is that when everyone agrees something is about to happen, another event happens. That’s why you have to be a contrarian sometimes. The Trade I Missed There were other factors at play. Insider buying is picking up. I saw a lot of purchases at companies like General Motors (GM), General Electric (GE), and Aon (AON). But a new one really stood out, especially in an environment dominated by inflationary concerns. Howard Schultz, the interim CEO at Starbucks (SBUX), bought more than $9 million in company shares. It hit the headlines last night. The stock moved higher in premarket hours. I was bullish. Momentum was strong across the board for intraday trading. I planned to make a trade right when the market opened. By the end of the day, shares had rallied more than 8% on the news… and I missed the chance to buy cheap in-the-money calls that expired today. I should have… my gosh… I should have bought the $72.50 call when the market opened on SBUX. That call opened at $0.45. It closed at nearly $3.00. But I was on the phone. I missed the trade. By the time I looked at the option again, it had jumped to $1.05. Should I have chased the trade at that point? No. No, I should not. This market has been full of intraday moves that rocked up and down for several weeks. Chasing a trade is not a good idea. Based on previous patterns and uncertainties, we’ve seen selloffs that come midday. They didn’t come today. We saw a steady grind higher. I had a full schedule today. I couldn’t be at my screens all day. I couldn’t and wouldn’t chase SBUX all day. Yes, there was opportunity cost - but when life comes at you, there’s no reason to be bitter about a missed trade. There will be more opportunities in this market, full of wild intraday and multi-day swings. Getting too caught up on one trade - and yes, even if it would have returned nearly 900% - is never a good idea. It is what it is. Right now, we’re entering a very interesting period for the market. I’m becoming more bullish about a short-term bounce. However, I believe that a short-term bounce will shake out the shorts, lead to covering, and then fuel another move down with far less resistance. Cash remains your best friend. Momentum is red… Enjoy your weekend, [Garrett Sig] Garrett {NAME} Chief Analyst, American Markets [] --------------------------------------------------------------- [] [] I Missed This Trade... [Garrett Pic] Dear Investor, Today, I woke up more bullish than I was on March 17. A short-term pop felt like it was inevitable. I was ready to load up on a day-trade and bet big on the QQQ. And I was especially bullish on a consumer discretionary stock that had a big insider buy. My plan was in place at 9:23 am. But then I received a phone call. My project over in Europe is surprisingly doing well thanks to the shift in the winds on alternative energy. I was surprised… and happy. So, I talked to my project leader… for an hour. As a result, I missed a trade that would have paid off big. I was mad for five minutes. But I quickly got over it. I’ll explain why. And one of the most important lessons of this market. Don’t Chase… Ever I was bullish today for several reasons. First, the VIX hasn’t elevated as high as most investors thought it would. Most people think that the VIX must move higher when stocks are moving lower. But that’s not how it works. The reality is that most traders are already hedged, and without more hedging entering the fold, the VIX doesn’t start to go bonkers. Next, the VIX is historically low when you consider the severity of the downside move. There is short-term bias in this market, and people think that the VIX will just run to 40, 60, or 80. That’s not how it works. I was also bullish today because I’ve seen this hyper-bearish pattern three times in 2022 and in late March 2022. Sometimes things get so bearish that you have to become bullish. One of the finest rules is that when everyone agrees something is about to happen, another event happens. That’s why you have to be a contrarian sometimes. The Trade I Missed There were other factors at play. Insider buying is picking up. I saw a lot of purchases at companies like General Motors (GM), General Electric (GE), and Aon (AON). But a new one really stood out, especially in an environment dominated by inflationary concerns. Howard Schultz, the interim CEO at Starbucks (SBUX), bought more than $9 million in company shares. It hit the headlines last night. The stock moved higher in premarket hours. I was bullish. Momentum was strong across the board for intraday trading. I planned to make a trade right when the market opened. By the end of the day, shares had rallied more than 8% on the news… and I missed the chance to buy cheap in-the-money calls that expired today. I should have… my gosh… I should have bought the $72.50 call when the market opened on SBUX. That call opened at $0.45. It closed at nearly $3.00. But I was on the phone. I missed the trade. By the time I looked at the option again, it had jumped to $1.05. Should I have chased the trade at that point? No. No, I should not. This market has been full of intraday moves that rocked up and down for several weeks. Chasing a trade is not a good idea. Based on previous patterns and uncertainties, we’ve seen selloffs that come midday. They didn’t come today. We saw a steady grind higher. I had a full schedule today. I couldn’t be at my screens all day. I couldn’t and wouldn’t chase SBUX all day. Yes, there was opportunity cost - but when life comes at you, there’s no reason to be bitter about a missed trade. There will be more opportunities in this market, full of wild intraday and multi-day swings. Getting too caught up on one trade - and yes, even if it would have returned nearly 900% - is never a good idea. It is what it is. Right now, we’re entering a very interesting period for the market. I’m becoming more bullish about a short-term bounce. However, I believe that a short-term bounce will shake out the shorts, lead to covering, and then fuel another move down with far less resistance. Cash remains your best friend. Momentum is red… Enjoy your weekend, [Garrett Sig] Garrett {NAME} Chief Analyst, American Markets --------------------------------------------------------------- [] 20-year Trading Legend Reveals His Daily "Hot List" Of Stocks... [rob booker]( [CLICK HERE TO GET THE LIST!]( --------------------------------------------------------------- [] [] 20-year Trading Legend Reveals His Daily "Hot List" Of Stocks... [rob booker]( [CLICK HERE TO GET THE LIST!]( --------------------------------------------------------------- [] [] [] BioNTech Share Is Favorably Valued [Bauer Pic]Dear Investor, Today we are talking about the Mainz-based biotech company BioNTech (BNTX). Similar to HelloFresh, this "fallen angel" is well worth a look. COVID-19 Vaccine Brings Breakthrough Founded in 2008, this biotech company was one of the big beneficiaries of the COVID-19 pandemic, probably the biggest in Germany. Biontech specializes in immunotherapies and conducts research on novel vaccines that - like the COVID-19 vaccine - are based on mRNA technology. The development of the COVID-19 vaccine, which was marketed jointly with the U.S. company Pfizer, brought a commercial breakthrough for the Mainz-based company. In 2020, sales more than quadrupled to 482.3 million euros. Net income was 15.2 million euros, compared with a loss of 179.2 million euros the year before. The big push then came last year. Sales increased 39-fold to 19.0 billion euros. Earnings per share exploded more than 700-fold to 42.18 euros. In 2020, earnings per share had amounted to just 6 cents. Good Start To The New Financial Year At the beginning of this week, BioNTech presented its results for the first quarter of 2022 and was once again able to convince. Sales more than tripled from2.05 billion euros to 6.37 billion euros. The same applies to net profit, which grew from 1.13 billion euros to 3.70 billion euros compared to the same quarter last year. In presenting its figures, the company reiterated its sales guidance for its COVID-19 vaccine. For the current year, management expects revenues of between 13 and 17 billion euros. Together with its U.S. partner Pfizer, Biontech is also evaluating potential successor versions of its current COVID-19 vaccine. BioNTech Research In The Cancer Field The high revenues generated by the COVID-19 vaccine have put the company in an extremely comfortable financial position, giving it the opportunity to once again significantly increase the pace of research in other areas. For example, BioNTech currently has over a dozen cancer therapies in clinical trials. The Mainz-based company recently presented initial data on a new treatment at the US cancer conference AACR. BioNTech combines a CAR-T cell therapy with an mRNA vaccine. The results so far are promising: tumors shrank or disappeared in six of the 16 patients. Favorable Valuation Opens Up Opportunities After soaring to new heights, the BioNTech share has lost around two-thirds of its value compared with its high in August last year. In turn, however, the key figures have improved significantly. After the COVID-19 boost, analysts do expect a drop in profits this year. Nevertheless, the price-earnings ratio (P/E) is just 4. A ridiculous valuation! [MAT Stock]( Against this background, the BioNTech share has plenty of room to aim for significantly higher prices again in the medium term. After all, the recent weakness did not reach the annual lows of early March. A first sign of a possible bottom formation. For risk-tolerant investors who do not shy away from high price fluctuations, it could be worthwhile to lie in wait and put the BioNTech share on the watch list. Best regards, [Bauer Sig] Dr. Gregor Bauer Chief Analyst, European Markets [] --------------------------------------------------------------- [] [] BioNTech Share Is Favorably Valued [Bauer Pic]Dear Investor, Today we are talking about the Mainz-based biotech company BioNTech (BNTX). Similar to HelloFresh, this "fallen angel" is well worth a look. COVID-19 Vaccine Brings Breakthrough Founded in 2008, this biotech company was one of the big beneficiaries of the COVID-19 pandemic, probably the biggest in Germany. Biontech specializes in immunotherapies and conducts research on novel vaccines that - like the COVID-19 vaccine - are based on mRNA technology. The development of the COVID-19 vaccine, which was marketed jointly with the U.S. company Pfizer, brought a commercial breakthrough for the Mainz-based company. In 2020, sales more than quadrupled to 482.3 million euros. Net income was 15.2 million euros, compared with a loss of 179.2 million euros the year before. The big push then came last year. Sales increased 39-fold to 19.0 billion euros. Earnings per share exploded more than 700-fold to 42.18 euros. In 2020, earnings per share had amounted to just 6 cents. Good Start To The New Financial Year At the beginning of this week, BioNTech presented its results for the first quarter of 2022 and was once again able to convince. Sales more than tripled from2.05 billion euros to 6.37 billion euros. The same applies to net profit, which grew from 1.13 billion euros to 3.70 billion euros compared to the same quarter last year. In presenting its figures, the company reiterated its sales guidance for its COVID-19 vaccine. For the current year, management expects revenues of between 13 and 17 billion euros. Together with its U.S. partner Pfizer, Biontech is also evaluating potential successor versions of its current COVID-19 vaccine. BioNTech Research In The Cancer Field The high revenues generated by the COVID-19 vaccine have put the company in an extremely comfortable financial position, giving it the opportunity to once again significantly increase the pace of research in other areas. For example, BioNTech currently has over a dozen cancer therapies in clinical trials. The Mainz-based company recently presented initial data on a new treatment at the US cancer conference AACR. BioNTech combines a CAR-T cell therapy with an mRNA vaccine. The results so far are promising: tumors shrank or disappeared in six of the 16 patients. Favorable Valuation Opens Up Opportunities After soaring to new heights, the BioNTech share has lost around two-thirds of its value compared with its high in August last year. In turn, however, the key figures have improved significantly. After the COVID-19 boost, analysts do expect a drop in profits this year. Nevertheless, the price-earnings ratio (P/E) is just 4. A ridiculous valuation! [MAT Stock]( Against this background, the BioNTech share has plenty of room to aim for significantly higher prices again in the medium term. After all, the recent weakness did not reach the annual lows of early March. A first sign of a possible bottom formation. For risk-tolerant investors who do not shy away from high price fluctuations, it could be worthwhile to lie in wait and put the BioNTech share on the watch list. Best regards, [Bauer Sig] Dr. Gregor Bauer Chief Analyst, European Markets --------------------------------------------------------------- [] [] “STOP WASTING TIME SEARCHING FOR DAILY TRADES…” Let a notorious 20-year trading veteran do it for you! Every morning for the last few months, this pro trader has been quietly sending out a list of his favorite high-potential stock picks to a small, select group of successful traders… And [open enrollment is still available to the public.]( A rare opportunity for everyday traders just like you! Every day, before the market even opens, you could be receiving this legendary trader’s personal “hot sheet” of top stock picks for the day. Stocks that have the highest probabilities of moving 5% to 10% in just a couple of hours each trading day. Giving you, starting as soon as tomorrow, a shot at making $490 (or more) every single day the market is open. All by simply trading off the same watch list of this seasoned professional trader. But you have to move fast… we don’t know how long this opportunity for the general public to join will last. [>>CLICK HERE NOW TO SIGN UP]( --------------------------------------------------------------- [] [] [] “STOP WASTING TIME SEARCHING FOR DAILY TRADES…” Let a notorious 20-year trading veteran do it for you! Every morning for the last few months, this pro trader has been quietly sending out a list of his favorite high-potential stock picks to a small, select group of successful traders… And [open enrollment is still available to the public.]( A rare opportunity for everyday traders just like you! Every day, before the market even opens, you could be receiving this legendary trader’s personal “hot sheet” of top stock picks for the day. Stocks that have the highest probabilities of moving 5% to 10% in just a couple of hours each trading day. Giving you, starting as soon as tomorrow, a shot at making $490 (or more) every single day the market is open. All by simply trading off the same watch list of this seasoned professional trader. But you have to move fast… we don’t know how long this opportunity for the general public to join will last. [>>CLICK HERE NOW TO SIGN UP]( --------------------------------------------------------------- [] [] Article Recap - [I Missed This Trade...](#i572731) - [BioNTech Share Is Favorably Valued](#i572028) - [“STOP WASTING TIME SEARCHING FOR DAILY TRADES...”](#156389) --------------------------------------------------------------- [] Article Recap - [I Missed This Trade...](#i572731) - [BioNTech Share Is Favorably Valued](#i572028) - [“STOP WASTING TIME SEARCHING FOR DAILY TRADES...”](#156389) --------------------------------------------------------------- [] © 2022 Godesburg Financial Publishing, Inc. DISCLAIMER: COMMUNICATIONS FROM GODESBURG FINANCIAL PUBLISHING (GFP) ARE FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY – NOT INVESTMENT ADVICE: GFP and all the services it offers are for educational and informational purposes only and should NOT be understood to be securities-related offers or solicitations. None of GFP’s communications should be considered or used as personalized investment advice. GFP recommends that you speak with a licensed professional before making any investment decision. RESULTS PRESENTED ARE NOT NECCESSARILY TYPICAL OR VERIFIED: GFP communications may include information regarding the historical trading performance of gurus in their services (all verified by a third party), as well as testimonials of non-employees depicting profitable investments and trades that are believed to be true based on the representations of the persons providing the testimonial of their own free will. Please be aware that the claims regarding investing or trading results of non-employees are not tracked by GFP nor can they be verified. As always, past performance is not necessarily indicative of future results. Therefore, results presented in this email should NOT be considered TYPICAL. Actual results can and will vary based on everything from experience, ability, risk mitigation practices, and market volatility... to the amount of money exposed in the investment or trade. Investing and trading are speculative and carry serious risk. You may lose some, all - or possibly more - than your original investment or trade. GODESBURG FINANCIAL PUBLISHING IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER: GFP, including its owners and employees, are NOT registered as securities broker-dealers, brokers, or any sort of registered investment advisors with the U.S. Securities and Exchange Commission, any state securities regulatory authorities, or any self-regulatory organizations. GODESBURG FINANCIAL PUBLISHING EMPLOYEES MAY HOLD SECURITIES DISCUSSED: If a writer holds any securities in a communication, it will be disclosed along with the information on the potential investment or trade. HIR, its owners or employees, have not been - or ever will be - paid by the issuer of a security mentioned in our services or communications. GFP, its owners and employees are paid entirely or in part from commissions based on sales of their services to subscribers. For more information, please visit [our disclaimer page here.]( Sent to: {EMAIL} [Unsubscribe]( Godesburg Financial Publishing Inc., 251 Little Falls Drive, Wilmington, DE 19808, United States [] © 2022 Godesburg Financial Publishing, Inc. DISCLAIMER: COMMUNICATIONS FROM GODESBURG FINANCIAL PUBLISHING (GFP) ARE FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY – NOT INVESTMENT ADVICE: GFP and all the services it offers are for educational and informational purposes only and should NOT be understood to be securities-related offers or solicitations. None of GFP’s communications should be considered or used as personalized investment advice. GFP recommends that you speak with a licensed professional before making any investment decision. RESULTS PRESENTED ARE NOT NECCESSARILY TYPICAL OR VERIFIED: GFP communications may include information regarding the historical trading performance of gurus in their services (all verified by a third party), as well as testimonials of non-employees depicting profitable investments and trades that are believed to be true based on the representations of the persons providing the testimonial of their own free will. Please be aware that the claims regarding investing or trading results of non-employees are not tracked by GFP nor can they be verified. As always, past performance is not necessarily indicative of future results. Therefore, results presented in this email should NOT be considered TYPICAL. Actual results can and will vary based on everything from experience, ability, risk mitigation practices, and market volatility... to the amount of money exposed in the investment or trade. Investing and trading are speculative and carry serious risk. You may lose some, all - or possibly more - than your original investment or trade. GODESBURG FINANCIAL PUBLISHING IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER: GFP, including its owners and employees, are NOT registered as securities broker-dealers, brokers, or any sort of registered investment advisors with the U.S. Securities and Exchange Commission, any state securities regulatory authorities, or any self-regulatory organizations. GODESBURG FINANCIAL PUBLISHING EMPLOYEES MAY HOLD SECURITIES DISCUSSED: If a writer holds any securities in a communication, it will be disclosed along with the information on the potential investment or trade. HIR, its owners or employees, have not been - or ever will be - paid by the issuer of a security mentioned in our services or communications. GFP, its owners and employees are paid entirely or in part from commissions based on sales of their services to subscribers. For more information, please visit [our disclaimer page here.]( Sent to: {EMAIL} [Unsubscribe]( Godesburg Financial Publishing Inc., 251 Little Falls Drive, Wilmington, DE 19808, United States